Targeting T-cell migration in inflammatory bowel disease

Journal of Internal Medicine

Volumn 272, Issue 5, 2012, Pages 411-429

  Marsal, J ^a   Agace, W W ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Biologics; Dendritic cells; Gastroenterology; Homing molecules; Inflammatory bowel disease; T lymphocytes

Indexed keywords

2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; AJM 300; ALICAFORSEN; AMD 300; CCX 025; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; ETROLIZUMAB; FINGOLIMOD; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 21; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 7 RECEPTOR; JANUS KINASE 2; MDX 1100; MLN 3126; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PF 00547 659; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDOLIZUMAB; VERCIRNON; VERY LATE ACTIVATION ANTIGEN 4;

ANTIBODY SPECIFICITY; BRADYCARDIA; COLITIS; CROHN DISEASE; DRUG EFFICACY; EFFECTOR CELL; ENTERITIS; HUMAN; ILEITIS; IMMUNE SYSTEM; INFLAMMATION; INTESTINE MUCOSA; JC VIRUS; LAMINA PROPRIA; LYMPHOCYTE MIGRATION; MORBIDITY; NONHUMAN; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; REVIEW; T LYMPHOCYTE; TISSUE INJURY; TREATMENT RESPONSE; ULCERATIVE COLITIS; VIRUS INFECTION; VIRUS REACTIVATION;

BIOLOGICAL AGENTS; CELL MOVEMENT; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867904783     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02588.x     Document Type: Review

References (202)

1. Hao WL, Lee YK. Microflora of the gastrointestinal tract: a review. Methods Mol Biol 2004; 268: 491-502.
2. Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.
3. Collado MC, Isolauri E, Salminen S, Sanz Y. The impact of probiotic on gut health. Curr Drug Metab 2009; 10: 68-78.
4. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102: 448-55.
5. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407.
6. Pabst O, Herbrand H, Worbs T et al. Cryptopatches and isolated lymphoid follicles: dynamic lymphoid tissues dispensable for the generation of intraepithelial lymphocytes. Eur J Immunol 2005; 35: 98-107.
7. Cornes JS. Number, size, and distribution of Peyer's patches in the human small intestine: part I the development of Peyer's patches. Gut 1965; 6: 225-9.
8. Villablanca EJ, Cassani B, von Andrian UH, Mora JR. Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology 2011; 140: 1776-84.
9. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003; 3: 331-41.
10. Rescigno M, Urbano M, Valzasina B et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001; 2: 361-7.
11. Schulz O, Jaensson E, Persson EK et al. Intestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical dendritic cell functions. J Exp Med 2009; 206: 3101-14.
12. Neal MD, Leaphart C, Levy R et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 2006; 176: 3070-9.
13. Corthesy B. Roundtrip ticket for secretory IgA: role in mucosal homeostasis? J Immunol 2007; 178: 27-32.
14. McDole JR, Wheeler LW, McDonald KG et al. Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine. Nature 2012; 483: 345-9.
15. Macdonald TT. The gut is still the biggest lymphoid organ in the body. Mucosal Immunol 2008; 1: 246-7.
16. Crowe PT, Marsh MN. Morphometric analysis of intestinal mucosa. VI-Principles in enumerating intra-epithelial lymphocytes. Virchows Arch 1994; 424: 301-6.
17. Cheroutre H, Lambolez F, Mucida D. The light and dark sides of intestinal intraepithelial lymphocytes. Nat Rev Immunol 2011; 11: 445-56.
18. Brandtzaeg P, Farstad IN, Helgeland L. Phenotypes of T cells in the gut. Chem Immunol 1998; 71: 1-26.
19. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 2009; 27: 313-38.
20. Josefowicz SZ, Niec RE, Kim HY et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 2012; 482: 395-9.
21. Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-8.
22. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485-517.
23. Morrison PJ, Ballantyne SJ, Kullberg MC. Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity. Immunology 2011; 133: 397-408.
24. Esplugues E, Huber S, Gagliani N et al. Control of TH17 cells occurs in the small intestine. Nature 2011; 475: 514-8.
25. Hovhannisyan Z, Treatman J, Littman DR, Mayer L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 2011; 140: 957-65.
26. Orrhage K, Nord CE. Bifidobacteria and lactobacilli in human health. Drugs Exp Clin Res 2000; 26: 95-111.
27. Lundqvist C, Hammarstrom ML, Athlin L, Hammarstrom S. Isolation of functionally active intraepithelial lymphocytes and enterocytes from human small and large intestine. J Immunol Methods 1992; 152: 253-63.
28. Kagnoff MF. Current concepts in mucosal immunity. III. Ontogeny and function of gamma delta T cells in the intestine. Am J Physiol 1998; 274: G455-8.
29. Beagley KW, Fujihashi K, Lagoo AS et al. Differences in intraepithelial lymphocyte T cell subsets isolated from murine small versus large intestine. J Immunol 1995; 154: 5611-9.
30. Boll G, Rudolphi A, Spiess S, Reimann J. Regional specialization of intraepithelial T cells in the murine small and large intestine. Scand J Immunol 1995; 41: 103-13.
31. Moran AP, Gupta A, Joshi L. Sweet-talk: role of host glycosylation in bacterial pathogenesis of the gastrointestinal tract. Gut 2011; 60: 1412-25.
32. Ivanov II, McKenzie BS, Zhou L et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126: 1121-33.
33. Atarashi K, Tanoue T, Shima T et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011; 331: 337-41.
34. Agace WW. Tissue-tropic effector T cells: generation and targeting opportunities. Nat Rev Immunol 2006; 6: 682-92.
35. Sigmundsdottir H, Butcher EC. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol 2008; 9: 981-7.
36. Hart AL, Ng SC, Mann E, Al-Hassi HO, Bernardo D, Knight SC. Homing of immune cells: role in homeostasis and intestinal inflammation. Inflamm Bowel Dis 2010; 16: 1969-77.
37. Kunkel EJ, Campbell JJ, Haraldsen G et al. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000; 192: 761-8.
38. Papadakis KA, Prehn J, Nelson V et al. The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol 2000; 165: 5069-76.
39. Wurbel MA, Philippe JM, Nguyen C et al. The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double- and single-positive thymocytes expressing the TECK receptor CCR9. Eur J Immunol 2000; 30: 262-71.
40. Ericsson A, Kotarsky K, Svensson M, Sigvardsson M, Agace W. Functional characterization of the CCL25 promoter in small intestinal epithelial cells suggests a regulatory role for caudal-related homeobox (Cdx) transcription factors. J Immunol 2006; 176: 3642-51.
41. Berlin C, Berg EL, Briskin MJ et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993; 74: 185-95.
42. Briskin M, Winsor-Hines D, Shyjan A et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151: 97-110.
43. Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol 2008; 29: 514-22.
44. Siewert C, Menning A, Dudda J et al. Induction of organ-selective CD4+ regulatory T cell homing. Eur J Immunol 2007; 37: 978-89.
45. Lee JH, Kang SG, Kim CH. FoxP3+ T cells undergo conventional first switch to lymphoid tissue homing receptors in thymus but accelerated second switch to nonlymphoid tissue homing receptors in secondary lymphoid tissues. J Immunol 2007; 178: 301-11.
46. Wurbel MA, Malissen M, Guy-Grand D et al. Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor gammadelta(+) gut intraepithelial lymphocytes. Blood 2001; 98: 2626-32.
47. Uehara S, Grinberg A, Farber JM, Love PE. A role for CCR9 in T lymphocyte development and migration. J Immunol 2002; 168: 2811-9.
48. Wurbel MA, Malissen M, Guy-Grand D, Malissen B, Campbell JJ. Impaired accumulation of antigen-specific CD8 lymphocytes in chemokine CCL25-deficient intestinal epithelium and lamina propria. J Immunol 2007; 178: 7598-606.
49. Stenstad H, Svensson M, Cucak H, Kotarsky K, Agace WW. Differential homing mechanisms regulate regionalized effector CD8alphabeta+ T cell accumulation within the small intestine. Proc Nat Acad Sci USA 2007; 104: 10122-7.
50. Stenstad H, Ericsson A, Johansson-Lindbom B et al. Gut-associated lymphoid tissue-primed CD4+ T cells display CCR9-dependent and -independent homing to the small intestine. Blood 2006; 107: 3447-54.
51. Annunziato F, Cosmi L, Liotta F et al. CXCR3 and alphaEbeta7 integrin identify a subset of CD8+ mature thymocytes that share phenotypic and functional properties with CD8+ gut intraepithelial lymphocytes. Gut 2006; 55: 961-8.
52. Heidemann J, Ogawa H, Rafiee P et al. Mucosal angiogenesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells. Am J Physiol Gastrointest Liver Physiol 2004; 286: G1059-68.
53. Wright N, Hidalgo A, Rodriguez-Frade JM et al. The chemokine stromal cell-derived factor-1 alpha modulates alpha 4 beta 7 integrin-mediated lymphocyte adhesion to mucosal addressin cell adhesion molecule-1 and fibronectin. J Immunol 2002; 168: 5268-77.
54. Oyama T, Miura S, Watanabe C et al. CXCL12 and CCL20 play a significant role in mucosal T-lymphocyte adherence to intestinal microvessels in mice. Microcirculation 2007; 14: 753-66.
55. Lefrancois L, Parker CM, Olson S, Muller W, Wagner N, Puddington L. The role of beta7 integrins in CD8 T cell trafficking during an antiviral immune response. J Exp Med 1999; 189: 1631-8.
56. Svensson M, Marsal J, Ericsson A et al. CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa. J Clin Invest 2002; 110: 1113-21.
57. Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 2002; 195: 135-41.
58. Johansson-Lindbom B, Svensson M, Wurbel M-A, Malissen B, Márquez G, Agace W. Selective generation of gut-tropic T cells in gut associated lymphoid tissue (GALT); requirement for GALT dendritic cells and adjuvant. J Exp Med 2003; 198: 963-9.
59. Mora JR, Bono MR, Manjunath N et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003; 424: 88-93.
60. Stagg AJ, Kamm MA, Knight SC. Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. Eur J Immunol 2002; 32: 1445-54.
61. Jaensson E, Uronen-Hansson H, Pabst O et al. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J Exp Med 2008; 205: 2139-49.
62. Johansson-Lindbom B, Svensson M, Pabst O et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med 2005; 202: 1063-73.
63. Annacker O, Coombes JL, Malmstrom V et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 2005; 202: 1051-61.
64. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic Acid imprints gut-homing specificity on T cells. Immunity 2004; 21: 527-38.
65. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007; 204: 1757-64.
66. Svensson M, Johansson-Lindbom B, Zapata F et al. Retinoic acid receptor signaling levels and antigen dose regulate gut homing receptor expression on CD8+ T cells. Mucosal Immunol 2008; 1: 38-48.
67. Jaensson-Gyllenback E, Kotarsky K, Zapata F et al. Bile retinoids imprint intestinal CD103+ dendritic cells with the ability to generate gut-tropic T cells. Mucosal Immunol 2011; 4: 438-47.
68. Agace WW, Persson EK. How vitamin A metabolizing dendritic cells are generated in the gut mucosa. Trends Immunol 2012; 33: 42-8.
69. Molenaar R, Knippenberg M, Goverse G et al. Expression of retinaldehyde dehydrogenase enzymes in mucosal dendritic cells and gut-draining lymph node stromal cells is controlled by dietary vitamin A. J Immunol 2011; 186: 1934-42.
70. Cassani B, Villablanca EJ, Quintana FJ et al. Gut-tropic T cells that express integrin alpha4beta7 and CCR9 are required for induction of oral immune tolerance in mice. Gastroenterology 2011; 141: 2109-18.
71. Yokota A, Takeuchi H, Maeda N et al. GM-CSF and IL-4 synergistically trigger dendritic cells to acquire retinoic acid-producing capacity. Int Immunol 2009; 21: 361-77.
72. McDonald KG, Leach MR, Brooke KW et al. Epithelial expression of the cytosolic retinoid chaperone cellular retinol binding protein II is essential for in vivo imprinting of local gut dendritic cells by lumenal retinoids. Am J Pathol 2012; 180: 984-97.
73. Atreya R, Neurath MF. New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol 2008; 1: 175-82.
74. Jacobsen BA, Fallingborg J, Rasmussen HH et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol 2006; 18: 601-6.
75. Kappelman MD, Rifas-Shiman SL, Kleinman K et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-9.
76. Pizzi LT, Weston CM, Goldfarb NI et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 47-52.
77. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-94.
78. Travis SP, Farrant JM, Ricketts C et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
79. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010; 28: 573-621.
80. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-17.
81. Sturm A, de Souza HS, Fiocchi C. Mucosal T cell proliferation and apoptosis in inflammatory bowel disease. Curr Drug Targets 2008; 9: 381-7.
82. Kobayashi K, Asakura H, Hamada Y et al. T lymphocyte subpopulations and immunoglobulin-containing cells in the colonic mucosa of ulcerative colitis; a morphometric and immunohistochemical study. J Clin Lab Immunol 1988; 25: 63-8.
83. Kullberg MC, Andersen JF, Gorelick PL et al. Induction of colitis by a CD4+ T cell clone specific for a bacterial epitope. Proc Nat Acad Sci USA 2003; 100: 15830-5.
84. Cong Y, Brandwein SL, McCabe RP et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998; 187: 855-64.
85. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993; 5: 1461-71.
86. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994; 179: 589-600.
87. Tajima M, Wakita D, Noguchi D et al. IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells. J Exp Med 2008; 205: 1019-27.
88. Okamoto S, Watanabe M, Yamazaki M et al. A synthetic mimetic of CD4 is able to suppress disease in a rodent model of immune colitis. Eur J Immunol 1999; 29: 355-66.
89. Oyama Y, Craig RM, Traynor AE et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 2005; 128: 552-63.
90. Pospai D, Rene E, Fiasse R et al. Crohn's disease stable remission after human immunodeficiency virus infection. Dig Dis Sci 1998; 43: 412-9.
91. Ina K, Itoh J, Fukushima K et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999; 163: 1081-90.
92. Boirivant M, Marini M, Di Felice G et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999; 116: 557-65.
93. Maynard CL, Weaver CT. Intestinal effector T cells in health and disease. Immunity 2009; 31: 389-400.
94. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009; 58: 1152-67.
95. Gijsbers K, Geboes K, Van Damme J. Chemokines in gastrointestinal disorders. Curr Drug Targets 2006; 7: 47-64.
96. Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-62.
97. Brand S, Hofbauer K, Dambacher J et al. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype. Am J Gastroenterol 2006; 101: 99-106.
98. Seiderer J, Dambacher J, Leistner D et al. Genotype-phenotype analysis of the CXCL16 p.Ala181Val polymorphism in inflammatory bowel disease. Clin immunol 2008; 127: 49-55.
99. Yuan YH, ten Hove T, The FO, Slors JF, van Deventer SJ, te Velde AA. Chemokine receptor CXCR3 expression in inflammatory bowel disease. Inflamm Bowel Dis 2001; 7: 281-6.
100. Annunziato F, Cosmi L, Galli G et al. Assessment of chemokine receptor expression by human Th1 and Th2 cells in vitro and in vivo. J Leukoc Biol 1999; 65: 691-9.
101. Scheerens H, Hessel E, de Waal-Malefyt R, Leach MW, Rennick D. Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL-10-/- mice and Rag-2-/- mice reconstituted with CD4+ CD45RBhigh T cells. Eur J Immunol 2001; 31: 1465-74.
102. Andres PG, Beck PL, Mizoguchi E et al. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J Immunol 2000; 164: 6303-12.
103. Puleston J, Cooper M, Murch S et al. A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel disease. Aliment Pharmacol Ther 2005; 21: 109-20.
104. Connor SJ, Paraskevopoulos N, Newman R et al. CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease. Gut 2004; 53: 1287-94.
105. Sans M, Danese S, de la Motte C et al. Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease. Gastroenterology 2007; 132: 139-53.
106. Dotan I, Werner L, Vigodman S et al. CXCL12 is a constitutive and inflammatory chemokine in the intestinal immune system. Inflamm Bowel Dis 2010; 16: 583-92.
107. Diegelmann J, Seiderer J, Niess JH et al. Expression and regulation of the chemokine CXCL16 in Crohn's disease and models of intestinal inflammation. Inflamm Bowel Dis 2010; 16: 1871-81.
108. Papadakis KA, Prehn J, Moreno ST et al. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 2001; 121: 246-54.
109. Arijs I, De Hertogh G, Machiels K et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol 2011; 106: 748-61.
110. Hosoe N, Miura S, Watanabe C et al. Demonstration of functional role of TECK/CCL25 in T lymphocyte-endothelium interaction in inflamed and uninflamed intestinal mucosa. Am J Physiol Gastrointest Liver Physiol 2004; 286: G458-66.
111. Rivera-Nieves J, Ho J, Bamias G et al. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 2006; 131: 1518-29.
112. Apostolaki M, Manoloukos M, Roulis M et al. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology 2008; 134: 2025-35.
113. Wermers JD, McNamee EN, Wurbel MA, Jedlicka P, Rivera-Nieves J. The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice. Gastroenterology 2011; 140: 1526-35 e1523.
114. Wei Z, Ungashe S, Rubas W et al. Poster: a new approach for oral therapy in IBD: TRAFICET-EN, an antagonist for CCR9 - efficacy in preclinical models and early clinical data. Digestive Disease Week. Chicago, IL; 2005.
115. Eksteen B, Adams DH. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs 2010; 13: 472-781.
116. Walters MJ, Wang Y, Lai N et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2010; 335: 61-9.
117. Bekker P, Schreiber S, Keshav S et al. 2007. Abstract: PROTECT-1, a prospective randomized oral therapy evaluation of CCX282-B (TRAFICET-EN) in Crohn's disease trial. United European Gastroenterology Week. Paris, France.
118. ™) maintained remission of Crohn's disease in PROTECT-1 Study. Gastroenterology 2010; 138: S86.
119. Wurbel MA, Malissen B, Campbell JJ. Complex regulation of CCR9 at multiple discrete stages of T cell development. Eur J Immunol 2006; 36: 73-81.
120. Kamada N, Hisamatsu T, Okamoto S et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 2008; 118: 2269-80.
121. Sasaki S, Yoneyama H, Suzuki K et al. Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival. Eur J Immunol 2002; 32: 3197-205.
122. Bauer C, Loher F, Dauer M et al. The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-alpha mRNA expression. Dig Dis Sci 2007; 52: 1642-52.
123. Suzuki K, Kawauchi Y, Palaniyandi SS et al. Blockade of interferon-gamma-inducible protein-10 attenuates chronic experimental colitis by blocking cellular trafficking and protecting intestinal epithelial cells. Pathol Int 2007; 57: 413-20.
124. Singh UP, Singh S, Taub DD, Lillard JW Jr. Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice. J Immunol 2003; 171: 1401-6.
125. Mikami S, Nakase H, Yamamoto S et al. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis. J Pharmacol Exp Ther 2008; 327: 383-92.
126. Teramoto K, Miura S, Tsuzuki Y et al. Increased lymphocyte trafficking to colonic microvessels is dependent on MAdCAM-1 and C-C chemokine mLARC/CCL20 in DSS-induced mice colitis. Clin Exp Immunol 2005; 139: 421-8.
127. Varona R, Cadenas V, Flores J, Martinez AC, Marquez G. CCR6 has a non-redundant role in the development of inflammatory bowel disease. Eur J Immunol 2003; 33: 2937-46.
128. Katchar K, Kelly CP, Keates S, O'Brien MJ, Keates AC. MIP-3alpha neutralizing monoclonal antibody protects against TNBS-induced colonic injury and inflammation in mice. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1263-71.
129. Khan WI, Motomura Y, Wang H et al. Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells. Am J Physiol Gastrointest Liver Physiol 2006; 291: G803-11.
130. Platt AM, Bain CC, Bordon Y, Sester DP, Mowat AM. An independent subset of TLR expressing CCR2-dependent macrophages promotes colonic inflammation. J Immunol 2010; 184: 6843-54.
131. Takada Y, Hisamatsu T, Kamada N et al. Monocyte chemoattractant protein-1 contributes to gut homeostasis and intestinal inflammation by composition of IL-10-producing regulatory macrophage subset. J Immunol 2010; 184: 2671-6.
132. Nishimura M, Kuboi Y, Muramoto K, Kawano T, Imai T. Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann N Y Acad Sci 2009; 1173: 350-6.
133. Niess JH, Adler G. Enteric flora expands gut lamina propria CX3CR1+ dendritic cells supporting inflammatory immune responses under normal and inflammatory conditions. J Immunol 2010; 184: 2026-37.
134. Medina-Contreras O, Geem D, Laur O et al. CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J Clin Investig 2011; 121: 4787-95.
135. Mayer L, Sandborn WJ, Stepanov Y, Maccarone J 2010. A Randomized Placebo-Controlled Trial of MDX-1100, an Anti-IP-10 Antibody, for Moderately-to-Severely Active Ulcerative Colitis (UC). DDW 2010:Abstract 711a.
136. Tokuyama H, Ueha S, Kurachi M et al. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int Immunol 2005; 17: 1023-34.
137. Streeter PR, Berg EL, Rouse BT, Bargatze RF, Butcher EC. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature 1988; 331: 41-6.
138. Berlin C, Bargatze RF, Campbell JJ et al. alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 1995; 80: 413-22.
139. Souza HS, Elia CC, Spencer J, MacDonald TT. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut 1999; 45: 856-63.
140. Hamann A, Andrew DP, Jablonski-Westrich D, Holzmann B, Butcher EC. Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol 1994; 152: 3282-93.
141. Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 1997; 158: 2099-106.
142. Kato S, Hokari R, Matsuzaki K et al. Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J Pharmacol Exp Ther 2000; 295: 183-9.
143. Hesterberg PE, Winsor-Hines D, Briskin MJ et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996; 111: 1373-80.
144. Matsuzaki K, Tsuzuki Y, Matsunaga H et al. In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1. Clin Exp Immunol 2005; 140: 22-31.
145. Podolsky DK, Lobb R, King N et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Investig 1993; 92: 372-80.
146. Hokari R, Kato S, Matsuzaki K et al. Involvement of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the pathogenesis of granulomatous colitis in rats. Clin Exp Immunol 2001; 126: 259-65.
147. Park EJ, Mora JR, Carman CV et al. Aberrant activation of integrin alpha4beta7 suppresses lymphocyte migration to the gut. J Clin Investig 2007; 117: 2526-38.
148. Sydora BC, Wagner N, Lohler J et al. beta7 Integrin expression is not required for the localization of T cells to the intestine and colitis pathogenesis. Clin Exp Immunol 2002; 129: 35-42.
149. Rivera-Nieves J, Olson T, Bamias G et al. L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine. J Immunol 2005; 174: 2343-52.
150. Kuklin NA, Rott L, Darling J et al. alpha(4)beta(7) independent pathway for CD8(+) T cell-mediated intestinal immunity to rotavirus. J Clin Investig 2000; 106: 1541-52.
151. Feagan BG, Greenberg GR, Wild G et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352: 2499-507.
152. Parikh A, Leach T, Wyant T et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012; 18: 1470-1479.
153. Feagan BG, Rutgeerts PJ, Sands BE et al. 2012. Vedolizumab induction therapy for ulcerative colitis: results of Gemini 1, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial. Digestive Disease Week. San Diego, CA. Abstract 943b.
154. Feagan BG, Greenberg GR, Wild G et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370-7.
155. Vermeire S, Ghosh S, Panes J et al. The mucosal addressin cell adhesion molecule antibody PF-00547, 659 in ulcerative colitis: a randomised study. Gut 2011; 60: 1068-75.
156. Rutgeerts P, Fedorak NR, Hommes D et al. A phase I study of rHuMab Beta7 in moderate to severe ulcerative colitis (UC). Gastroenterology 2011; 140: S125.
157. Burns RC, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Cominelli F, Ley K. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 2001; 121: 1428-36.
158. Marski M, Ye AL, Abraham C. CD18 is required for intestinal T cell responses at multiple immune checkpoints. J Immunol 2007; 178: 2104-12.
159. Sans M, Panes J, Ardite E et al. VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology 1999; 116: 874-83.
160. Soriano A, Salas A, Sans M et al. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest 2000; 80: 1541-51.
161. Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-25.
162. Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-83.
163. Bozic C, Richman S, Plavina T et al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011; 70: 742-50.
164. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438-46.
165. Kappos L, Bates D, Edan G et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10: 745-58.
166. Sugiura T, Kageyama S, Andou A et al. A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4+ T Cells in Mice. J Pharmacol Exp Ther 2012; [Epub ahead of print].
167. Takazoe M, Watanabe M, Kawaguchi T, Matumoto T, Oshitani N, Hiwatashi N. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 136: S1066 Digestive Disease Week.
168. Pavlick KP, Ostanin DV, Furr KL et al. Role of T-cell-associated lymphocyte function-associated antigen-1 in the pathogenesis of experimental colitis. Int Immunol 2006; 18: 389-98.
169. Ostanin DV, Furr KL, Pavlick KP et al. T cell-associated CD18 but not CD62L, ICAM-1, or PSGL-1 is required for the induction of chronic colitis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1706-14.
170. Abdelbaqi M, Chidlow JH, Matthews KM et al. Regulation of dextran sodium sulfate induced colitis by leukocyte beta 2 integrins. Lab Invest 2006; 86: 380-90.
171. Taniguchi T, Tsukada H, Nakamura H et al. Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats. J Gastroenterol Hepatol 1998; 13: 945-9.
172. Bennett CF, Kornbrust D, Henry S et al. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther 1997; 280: 988-1000.
173. Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007; 5: 215-20.
174. van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1415-25.
175. van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004; 53: 1646-51.
176. Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004; 19: 281-6.
177. Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Dal Pan G. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011; 65: 546-51.
178. Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005; 23: 127-59.
179. Oskouian B, Saba J. Sphingosine-1-phosphate metabolism and intestinal tumorigenesis: lipid signaling strikes again. Cell Cycle 2007; 6: 522-7.
180. Matloubian M, Lo CG, Cinamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-60.
181. Brinkmann V, Billich A, Baumruker T et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discovery 2010; 9: 883-97.
182. Budde K, Schmouder RL, Brunkhorst R et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002; 13: 1073-83.
183. Mizushima T, Ito T, Kishi D et al. Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm Bowel Dis 2004; 10: 182-92.
184. Daniel C, Sartory N, Zahn N, Geisslinger G, Radeke HH, Stein JM. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+ CD25+ regulatory T cells. J Immunol 2007; 178: 2458-68.
185. Daniel C, Sartory NA, Zahn N et al. FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions. Mol Immunol 2007; 44: 3305-16.
186. Deguchi Y, Andoh A, Yagi Y et al. The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice. Oncol Rep 2006; 16: 699-703.
187. Fujii R, Kanai T, Nemoto Y et al. FTY720 suppresses CD4+ CD44highCD62L- effector memory T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol 2006; 291: G267-74.
188. Song J, Matsuda C, Kai Y et al. A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. J Pharmacol Exp Ther 2008; 324: 276-83.
189. Koboziev I, Karlsson F, Zhang S, Grisham MB. Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies. Inflamm Bowel Dis 2011; 17: 1229-45.
190. Franke A, McGovern DP, Barrett JC et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-25.
191. Anderson CA, Boucher G, Lees CW et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246-52.
192. Su C. Outcomes of placebo therapy in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 328-33.
193. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14: 40-6.
194. Isaacs KL. How rapidly should remission be achieved? Dig Dis 2010; 28: 548-55.
195. Bloomgren G, Richman S, Hotermans C et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-80.
196. Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohn's Colitis 2010; 4: 511-22.
197. Hadis U, Wahl B, Schulz O et al. Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria. Immunity 2011; 34: 237-46.
198. Katz S "Mind the Gap": an unmet need for new therapy in IBD. J Clin Gastroenterol 2007; 41: 799-809.
199. Schwartz D. Anti-IL-12/23: the next big thing in IBD? Inflamm Bowel Dis 2009; 15: 1927-8.
200. Melmed GY, Targan SR. Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol 2010; 7: 110-7.
201. Villablanca EJ, Wang S, de Calisto J et al. MyD88 and retinoic acid signaling pathways interact to modulate gastrointestinal activities of dendritic cells. Gastroenterology 2011; 141: 176-85.
202. Persson EK, Jaensson E, Agace WW. The diverse ontogeny and function of murine small intestinal dendritic cell/macrophage subsets. Immunobiology 2010; 215: 692-7.